CO5570672A2 - Composicion farmaceutica para utilizarse para el tratamiento de malignidades, que comprende una combinacion de bisfosfonatos, un inhibidor de cox-2 y un taxol - Google Patents
Composicion farmaceutica para utilizarse para el tratamiento de malignidades, que comprende una combinacion de bisfosfonatos, un inhibidor de cox-2 y un taxolInfo
- Publication number
- CO5570672A2 CO5570672A2 CO04034537A CO04034537A CO5570672A2 CO 5570672 A2 CO5570672 A2 CO 5570672A2 CO 04034537 A CO04034537 A CO 04034537A CO 04034537 A CO04034537 A CO 04034537A CO 5570672 A2 CO5570672 A2 CO 5570672A2
- Authority
- CO
- Colombia
- Prior art keywords
- cox
- inhibitor
- bisphosphonate
- treatment
- pharmaceutical composition
- Prior art date
Links
- 229940122361 Bisphosphonate Drugs 0.000 title abstract 7
- 150000004663 bisphosphonates Chemical class 0.000 title abstract 6
- 229940111134 coxibs Drugs 0.000 title abstract 4
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 229930012538 Paclitaxel Natural products 0.000 title abstract 2
- 229960001592 paclitaxel Drugs 0.000 title abstract 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000003211 malignant effect Effects 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000010261 cell growth Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000006882 induction of apoptosis Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1.- Una composición farmacéutica para el tratamiento de malignidades, el cual comprende en combinación un bisfosfonato y un inhibidor de COX-2 para uso simultáneo, secuencial o separado.2.- El uso de un inhibidor de COX-2 para la preparación de un medicamento, para utilizarse en combinación con un bisfosfonato para el tratamiento de una enfermedad maligna.3.- Un método para tratar a un paciente que presenta una enfermedad maligna, que comprende administrar al paciente una cantidad efectiva de un bisfosfonato y una cantidad efectiva de un inhibidor de COX-2.4.- Una composición farmacéutica de acuerdo con la reivindicación 1, un uso de acuerdo con la reivindicación 2, o un método de acuerdo con la reivindicación 3, para la inhibición de crecimiento de célula cancerosa o inducción de apoptosis de célula cancerosa. 5.- Un método para tratar a un paciente que presenta una enfermedad maligna, que comprende administrar al paciente una cantidad efectiva de un bisfosfonato, una cantidad efectiva de un inhibidor de COX-2 y una cantidad efectiva de un taxol o un derivado del mismo.6.- Un método de acuerdo con la reivindicación 3 o 5, en donde el bisfosfonato es un N-bisfosfonato.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34592101P | 2001-10-19 | 2001-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5570672A2 true CO5570672A2 (es) | 2005-10-31 |
Family
ID=23357099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO04034537A CO5570672A2 (es) | 2001-10-19 | 2004-04-15 | Composicion farmaceutica para utilizarse para el tratamiento de malignidades, que comprende una combinacion de bisfosfonatos, un inhibidor de cox-2 y un taxol |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7345088B2 (es) |
| EP (1) | EP1443942B1 (es) |
| JP (1) | JP2005506371A (es) |
| KR (1) | KR20040066103A (es) |
| CN (1) | CN100372539C (es) |
| AT (1) | ATE382347T1 (es) |
| AU (1) | AU2002363089B2 (es) |
| BR (1) | BR0213410A (es) |
| CA (1) | CA2461085A1 (es) |
| CO (1) | CO5570672A2 (es) |
| DE (1) | DE60224429T2 (es) |
| DK (1) | DK1443942T3 (es) |
| EC (1) | ECSP045054A (es) |
| ES (1) | ES2301710T3 (es) |
| HK (1) | HK1080733A1 (es) |
| HU (1) | HUP0402061A3 (es) |
| IL (2) | IL161090A0 (es) |
| MX (1) | MXPA04003671A (es) |
| NO (1) | NO20042056L (es) |
| NZ (1) | NZ532282A (es) |
| PL (1) | PL367707A1 (es) |
| PT (1) | PT1443942E (es) |
| RU (1) | RU2317819C2 (es) |
| SI (1) | SI1443942T1 (es) |
| WO (1) | WO2003035081A1 (es) |
| ZA (1) | ZA200402089B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0204756D0 (en) * | 2002-02-28 | 2002-04-17 | Novartis Ag | Organic compounds |
| GB0328040D0 (en) * | 2003-12-03 | 2004-01-07 | Coleman Robert E | Pharmaceutical uses of bisphosphonates |
| FR2939314A1 (fr) * | 2008-12-04 | 2010-06-11 | Univ Victor Segalen Bordeaux 2 | Nouvelles compositions et methodes pour la potentialisation des signaux d'apoptose dans les cellules tumorales |
| AU2010278860B2 (en) | 2009-07-31 | 2016-05-26 | Thar Pharma, Llc | Crystallization method and bioavailability |
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US9340565B2 (en) | 2010-11-24 | 2016-05-17 | Thar Pharmaceuticals, Inc. | Crystalline forms |
| US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1187130A (zh) * | 1995-06-06 | 1998-07-08 | 麦克公司 | 用二磷酸盐预防与免疫抑制疗法有关的骨损失 |
| AU2713500A (en) * | 1998-12-23 | 2000-07-31 | G.D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| WO2001054688A1 (en) * | 2000-01-28 | 2001-08-02 | Merck & Co., Inc. | Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug |
-
2002
- 2002-10-18 AU AU2002363089A patent/AU2002363089B2/en not_active Ceased
- 2002-10-18 HU HU0402061A patent/HUP0402061A3/hu unknown
- 2002-10-18 PT PT02801899T patent/PT1443942E/pt unknown
- 2002-10-18 IL IL16109002A patent/IL161090A0/xx unknown
- 2002-10-18 MX MXPA04003671A patent/MXPA04003671A/es active IP Right Grant
- 2002-10-18 BR BR0213410-1A patent/BR0213410A/pt not_active IP Right Cessation
- 2002-10-18 RU RU2004115337/15A patent/RU2317819C2/ru not_active IP Right Cessation
- 2002-10-18 DK DK02801899T patent/DK1443942T3/da active
- 2002-10-18 EP EP02801899A patent/EP1443942B1/en not_active Expired - Lifetime
- 2002-10-18 PL PL02367707A patent/PL367707A1/xx not_active Application Discontinuation
- 2002-10-18 NZ NZ532282A patent/NZ532282A/en unknown
- 2002-10-18 CA CA002461085A patent/CA2461085A1/en not_active Abandoned
- 2002-10-18 WO PCT/EP2002/011696 patent/WO2003035081A1/en active IP Right Grant
- 2002-10-18 DE DE60224429T patent/DE60224429T2/de not_active Expired - Fee Related
- 2002-10-18 CN CNB028207823A patent/CN100372539C/zh not_active Expired - Fee Related
- 2002-10-18 KR KR10-2004-7005630A patent/KR20040066103A/ko not_active Application Discontinuation
- 2002-10-18 ES ES02801899T patent/ES2301710T3/es not_active Expired - Lifetime
- 2002-10-18 AT AT02801899T patent/ATE382347T1/de not_active IP Right Cessation
- 2002-10-18 SI SI200230676T patent/SI1443942T1/sl unknown
- 2002-10-18 JP JP2003537648A patent/JP2005506371A/ja active Pending
- 2002-10-18 US US10/493,042 patent/US7345088B2/en not_active Expired - Fee Related
-
2004
- 2004-03-16 ZA ZA200402089A patent/ZA200402089B/en unknown
- 2004-03-25 IL IL161090A patent/IL161090A/en not_active IP Right Cessation
- 2004-04-08 EC EC2004005054A patent/ECSP045054A/es unknown
- 2004-04-15 CO CO04034537A patent/CO5570672A2/es not_active Application Discontinuation
- 2004-05-18 NO NO20042056A patent/NO20042056L/no not_active Application Discontinuation
-
2006
- 2006-01-18 HK HK06100803A patent/HK1080733A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2461085A1 (en) | 2003-05-01 |
| EP1443942B1 (en) | 2008-01-02 |
| DE60224429T2 (de) | 2008-12-18 |
| NZ532282A (en) | 2006-02-24 |
| HUP0402061A2 (hu) | 2005-02-28 |
| HUP0402061A3 (en) | 2007-05-29 |
| JP2005506371A (ja) | 2005-03-03 |
| ZA200402089B (en) | 2005-06-22 |
| PT1443942E (pt) | 2008-04-07 |
| MXPA04003671A (es) | 2005-06-20 |
| ECSP045054A (es) | 2004-05-28 |
| CN1703226A (zh) | 2005-11-30 |
| EP1443942A1 (en) | 2004-08-11 |
| BR0213410A (pt) | 2004-11-03 |
| PL367707A1 (en) | 2005-03-07 |
| RU2004115337A (ru) | 2005-04-20 |
| DE60224429D1 (de) | 2008-02-14 |
| AU2002363089B2 (en) | 2006-02-16 |
| KR20040066103A (ko) | 2004-07-23 |
| IL161090A0 (en) | 2004-08-31 |
| ES2301710T3 (es) | 2008-07-01 |
| CN100372539C (zh) | 2008-03-05 |
| WO2003035081A1 (en) | 2003-05-01 |
| HK1080733A1 (en) | 2006-05-04 |
| ATE382347T1 (de) | 2008-01-15 |
| US7345088B2 (en) | 2008-03-18 |
| IL161090A (en) | 2010-04-15 |
| RU2317819C2 (ru) | 2008-02-27 |
| SI1443942T1 (sl) | 2008-08-31 |
| NO20042056L (no) | 2004-05-18 |
| DK1443942T3 (da) | 2008-05-19 |
| US20050014726A1 (en) | 2005-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9715022A (pt) | Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada | |
| AR049985A1 (es) | Tratamiento de combinacion para enfermedades malignas no hematologicas | |
| AR033175A1 (es) | Usos farmaceuticos de bisfosfonatos | |
| ES2162393T3 (es) | Terapia de combinacion para erradicar el hcv-rna detectable en pacientes con infeccion de hepatitis c cronica. | |
| BRPI0207961B8 (pt) | uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos. | |
| CR11486A (es) | Tratamiento de cancer uterino y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes anti-tumorales | |
| BR0115109A (pt) | Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese | |
| AR029763A1 (es) | Uso de una combinacion de una nsaid y un inhibidor de quinasa egfr para la manufactura de un medicamento para el tratamiento o inhibicion de polipos colonicos y cancer colorectal, composicion farmaceutica y medicamento | |
| AR042051A1 (es) | Tratamiento combinado contra el cancer con un compuesto anti-cancerigeno activado por glutationa s- transferasa (gst) y otro tratamiento contra el cancer | |
| BR0115162A (pt) | Tratamentos antitumorais eficazes | |
| BRPI0507482A (pt) | combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap | |
| BRPI0415896A (pt) | combinações compreendendo um inibidor de hsp90 e um inibidor de fosfodiesterase para tratamento ou prevenção de neoplasia | |
| HK1080733A1 (en) | Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol | |
| Buckley et al. | Multiple keratoses and squamous carcinoma after PUVA treatment of vitiligo | |
| BRPI0415215B8 (pt) | uso de polifenol na preparação de medicamento | |
| BR0313081A (pt) | Combinação de um inibidor de aromatase com um bisfosfanato | |
| AR048806A1 (es) | Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio | |
| AR036321A1 (es) | Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia. | |
| HUP9801022A2 (hu) | Eljárás aldóz reduktáz inhibítor alkalmazása diabetikus szívizom-betegség megelőzésére vagy megfordítására | |
| UY30557A1 (es) | Tratamiento y prevencion de la fibrosis intestinal | |
| AR024981A1 (es) | Composicion para la prevencion y el tratamiento de las disfunciones y enfermedades del rinon | |
| HUP0301276A2 (hu) | Kombinációs terápia ösztrogénérzékeny betegségek kezelésére | |
| BR0315374A (pt) | Compostos orgânicos | |
| AR027677A1 (es) | Una composicion farmaceutica terapeutica que comprende camptotecina y ciclofosfamida para el tratamiento del cancer | |
| BRPI0409870A (pt) | uso de irinotecano para tratamento de cáncer de mama resistente |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted | ||
| FD | Application lapsed |